Progress in understanding humoral rejection in kidney transplantation: implications for patient management.
After more than 40 years of clinical renal transplantation, the contribution of humoral immunity to the pathogenesis of allograft rejection is progressively being clarified. With the advent of a new generation of immunosuppressive agents, the production and consequences of anti-donor alloantibodies can now be controlled. In the upcoming years, immunosuppressive regimens that will specifically control both T- and B-cell responses may further improve long-term allograft survival, if the immunosuppressive efficacy of such regimens is not hampered by an increase in infectious, neoplastic or cardio-vascular complications.
Pascual
M A
MA
Crespo
M
M
Tolkoff-Rubin
N
N
D000017:ABO Blood-Group System / Q000276:immunology; D000208:Acute Disease; D000917:Antibody Formation; D000920:Antibody-Dependent Cell Cytotoxicity; D002908:Chronic Disease; D003181:Complement C4 / Q000276:immunology; D015935:Complement C4b; D006084:Graft Rejection / Q000188:drug therapy / Q000276:immunology* / Q000517:prevention & control; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007518:Isoantibodies / Q000096:biosynthesis / Q000276:immunology*; D016030:Kidney Transplantation / Q000276:immunology*; D009173:Mycophenolic Acid / Q000627:therapeutic use; D010446:Peptide Fragments / Q000276:immunology; D010956:Plasmapheresis; D016559:Tacrolimus / Q000627:therapeutic use
D000017:ABO Blood-Group System; D003181:Complement C4; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D007518:Isoantibodies; D010446:Peptide Fragments; D015935:Complement C4b; C032261:complement C4d; D009173:Mycophenolic Acid; D016559:Tacrolimus